CD274 and neoplasm: The CHOICE study observed inter- and intra-tumor heterogeneity of PD-L1 expression (Fig. 6), which could contribute to challenges of utilizing PD-L1 expression as a companion diagnostic marker for predicting the response from anti-PD therapies.